Cargando…

Multimarker profiling identifies protective and harmful immune processes in heart failure: findings from BIOSTAT-CHF

AIMS: The exploration of novel immunomodulatory interventions to improve outcome in heart failure (HF) is hampered by the complexity/redundancies of inflammatory pathways, which remain poorly understood. We thus aimed to investigate the associations between the activation of diverse immune processes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Markousis-Mavrogenis, George, Tromp, Jasper, Ouwerkerk, Wouter, Ferreira, João Pedro, Anker, Stefan D, Cleland, John G, Dickstein, Kenneth, Filippatos, Gerasimos, Lang, Chim C, Metra, Marco, Samani, Nilesh J, de Boer, Rudolf A, van Veldhuisen, Dirk J, Voors, Adriaan A, van der Meer, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239579/ https://www.ncbi.nlm.nih.gov/pubmed/34264317 http://dx.doi.org/10.1093/cvr/cvab235

Ejemplares similares

Impact of mitral regurgitation in patients with worsening heart failure: insights from BIOSTAT‐CHF
por: Pagnesi, Matteo, et al.
Publicado: (2021)

Additional burden of iron deficiency in heart failure patients beyond the cardio‐renal anaemia syndrome: findings from the BIOSTAT‐CHF study
por: Alnuwaysir, Ridha I.S., et al.
Publicado: (2021)

Corrigendum to: Multimarker profiling identifies protective and harmful immune processes in heart failure: findings from BIOSTAT-CHF
Publicado: (2022)

Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction
por: Woolley, Rebecca J., et al.
Publicado: (2021)

Concentric vs. eccentric remodelling in heart failure with reduced ejection fraction: clinical characteristics, pathophysiology and response to treatment
por: Nauta, Jan F., et al.
Publicado: (2019)

Biomarker changes as surrogate endpoints in early‐phase trials in heart failure with reduced ejection fraction
por: Savarese, Gianluigi, et al.
Publicado: (2022)

A Clinical Tool to Predict Low Serum Selenium in Patients with Worsening Heart Failure
por: Al-Mubarak, Ali A., et al.
Publicado: (2020)

What is the added value of the waist‐to‐hip ratio on top of the BIOSTAT risk prediction model in patients with heart failure? Reply
por: Streng, Koen W., et al.
Publicado: (2018)

Dipeptidyl peptidase 3, a marker of the antagonist pathway of the renin–angiotensin–aldosterone system in patients with heart failure
por: Boorsma, Eva M., et al.
Publicado: (2021)

The role of cathepsin D in the pathophysiology of heart failure and its potentially beneficial properties: a translational approach
por: Hoes, Martijn F., et al.
Publicado: (2019)

Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction
por: ter Maaten, Jozine M., et al.
Publicado: (2020)

The value of spot urinary creatinine as a marker of muscle wasting in patients with new‐onset or worsening heart failure
por: Pandhi, Paloma, et al.
Publicado: (2021)

Clinical impact of changes in mitral regurgitation severity after medical therapy optimization in heart failure
por: Pagnesi, Matteo, et al.
Publicado: (2022)

Clinical implications of left atrial changes after optimization of medical therapy in patients with heart failure
por: Inciardi, Riccardo M., et al.
Publicado: (2022)

Perceived risk profile and treatment optimization in heart failure: an analysis from BIOlogy Study to TAilored Treatment in chronic heart failure
por: Kobayashi, Masatake, et al.
Publicado: (2021)

Clinical and prognostic associations of autoantibodies recognizing adrenergic/muscarinic receptors in patients with heart failure
por: Markousis-Mavrogenis, George, et al.
Publicado: (2023)

Prognostic significance of changes in heart rate following uptitration of beta-blockers in patients with sub-optimally treated heart failure with reduced ejection fraction in sinus rhythm versus atrial fibrillation
por: Mordi, Ify R., et al.
Publicado: (2019)

Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin–angiotensin–aldosterone inhibitors
por: Sama, Iziah E, et al.
Publicado: (2020)

Impaired High‐Density Lipoprotein Function in Patients With Heart Failure
por: Emmens, Johanna E., et al.
Publicado: (2021)

Neutrophil‐to‐lymphocyte ratio and outcomes in patients with new‐onset or worsening heart failure with reduced and preserved ejection fraction
por: Curran, Fraser M., et al.
Publicado: (2021)

Insulin‐like growth factor binding protein 7 (IGFBP7), a link between heart failure and senescence
por: Bracun, Valentina, et al.
Publicado: (2022)

Pathophysiological pathways related to high plasma growth differentiation factor 15 concentrations in patients with heart failure
por: Ceelen, Daan, et al.
Publicado: (2022)

Albuminuria as a marker of systemic congestion in patients with heart failure
por: Boorsma, Eva M, et al.
Publicado: (2022)

A network analysis to identify pathophysiological pathways distinguishing ischaemic from non‐ischaemic heart failure
por: Sama, Iziah E., et al.
Publicado: (2020)

Systemic oxidative stress associates with disease severity and outcome in patients with new-onset or worsening heart failure
por: de Koning, Marie-Sophie L. Y., et al.
Publicado: (2023)

Clinical implications of low estimated protein intake in patients with heart failure
por: Streng, Koen W., et al.
Publicado: (2022)

Pathophysiological pathways in patients with heart failure and atrial fibrillation( )
por: Santema, Bernadet T, et al.
Publicado: (2021)

Using matrix assisted laser desorption ionisation mass spectrometry (MALDI-MS) profiling in order to predict clinical outcomes of patients with heart failure
por: Cao, Thong Huy, et al.
Publicado: (2018)

Plasma proteomic approach in patients with heart failure: insights into pathogenesis of disease progression and potential novel treatment targets
por: Cao, Thong H., et al.
Publicado: (2019)

Genetic risk and atrial fibrillation in patients with heart failure
por: Kloosterman, Mariëlle, et al.
Publicado: (2020)

The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure
por: Santema, Bernadet T., et al.
Publicado: (2019)

Correction to: The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure
por: Santema, Bernadet T., et al.
Publicado: (2020)

Quality of life in men and women with heart failure: association with outcome, and comparison between the Kansas City Cardiomyopathy Questionnaire and the EuroQol 5 dimensions questionnaire
por: Ravera, Alice, et al.
Publicado: (2021)

Iron deficiency in worsening heart failure is associated with reduced estimated protein intake, fluid retention, inflammation, and antiplatelet use
por: van der Wal, Haye H, et al.
Publicado: (2019)

Whole blood transcriptomic profiling identifies molecular pathways related to cardiovascular mortality in heart failure
por: Nath, Mintu, et al.
Publicado: (2022)

Selenium and outcome in heart failure
por: Bomer, Nils, et al.
Publicado: (2019)

Biostatic Immunities of the Jewish Race in Europe
Publicado: (1869)

Clinical determinants and prognostic implications of renin and aldosterone in patients with symptomatic heart failure
por: Kobayashi, Masatake, et al.
Publicado: (2020)

Association of time‐to‐intravenous furosemide with mortality in acute heart failure: data from REPORT‐HF
por: Ouwerkerk, Wouter, et al.
Publicado: (2022)

Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency
por: van Veldhuisen, Dirk J., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_rmotqk87l46urocmb09222j5qb